PHARMACOKINETICS AND SAFETY OF RALTEGRAVIR IN 2 to 12 YEAR OLD CHILDREN WITH HIV RECEIVING RIFAMPICIN FOR TUBERCULOSIS

OBJECTIVES: Drug-drug interactions limit current antiretroviral (ARV) treatment options for HIV-infected children with tuberculosis (TB). Rifampicin (RIF) induces UDP-glucuronosyltransferase activity, accelerating the clearance of raltegravir (RAL). We sought to establish an optimal and safe dose of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:AIDS
Main Authors: MEYERS, Tammy, SAMSON, Pearl, ACOSTA, Edward P, MOYE, Jack, TOWNLEY, Ellen, BRADFORD, Sarah, MARILLO, Linda, DENSON, Kayla, HOVIND, Laura, SISE, Thucuma, TEPPLER, Hedy, MATHIBA, Sisinyana Ruth, MASENYA, Masebole, HESSELING, Anneke, COTTON, Mark F, KROGSTAD, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7232968/
https://ncbi.nlm.nih.gov/pubmed/31689263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0000000000002369
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados